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Background: Breast cancer may be classified into luminal A, luminal B, HER2+/ER-, basal-like and normal-like
subtypes based on gene expression profiling or immunohistochemical (IHC) characteristics. The aim of our study is
to show the molecular profile characteristic of breast cancer in the North African population of Morocco. This work
showed preliminary results and correlations with clinicopathological and histological parameters. Three hundred
and ninety primary breast carcinomas tumor tissues were immunostained for ER, PR, HER2, CK5/6, CK8/18 and Ki67
using paraffin tissue.
Methods: We reviewed 390 cases of breast cancer diagnosed on January 2008 to December 2011 at the
Department of pathology, Hassan II teaching hospital, Fez, Morocco. Age, size tumor, metastatic profile, node
involvement profile, histological type and immunohistochemical profile were studied.
Results: The average age was 46 years; our patients were diagnosed late with a high average tumor size. Luminal B
subtype was more prevalent (41.8%), followed by luminal A (30.5%), basal-like (13, 6%), Her2-overexpressing (9, 2%),
and unclassified subtype (4.9%).
Conclusion: This study showed that molecular classification and biological profile may be different according to
geographical distribution, to encourage further studies to know the genomic profile of tumors and the
environment.
Virtual slide: http://www.diagnosticpathology.diagnomx.eu/vs/1675272504826544
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Breast cancer is a heterogeneous disease such that they
may have different prognoses and respond to therapy
differently despite similarities in histological types, grade
and stage. Based on the presence or absence of expres-
sion of the estrogen receptor (ER), breast cancer is
divided in two groups: ER+ and ER-. Genetic expression
profile has identified two subtypes of the ER+ tumors:
luminal A and luminal B. ER- tumors also include two
subtypes, the HER2+ and the basal type. These subtypes* Correspondence: hinde0012@hotmail.com
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reproduction in any medium, provided the ordiffer in their biology and both demonstrate short
disease-free periods after treatment and poorer outcome.
In Morocco, it’s the first cancer in women and is cur-
rently a major public health problem. The molecular
classification in breast carcinomas is now based upon
gene expression analysis using DNA microarrays and
allows to identify at least five groups: luminal A, luminal
B, HER2-overexpressing, basal-like and normal breast-
like [1-3]. However, large-scale subtyping using gene
expression profiling from formalin-fixed, paraffin-
embedded samples is not currently feasible and remains
very expensive. Therefore, immunohistochemical mar-
kers have been used as surrogates tools for DNAd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Immunohistochemical characterization of
molecular subtypes of breast cancer
Molecular subtype Immunohistochemical characterization
Luminal A ER (+) et Her-2 (-) et CK8/18 (+), Ki67<14%
Luminal B ER (+) et Her-2 (+)
ou ER (+), Her-2 (-) et Ki67>14%
Her-2 ER (-) et Her-2 (+)
Basal ER (-) et Her-2 (-) et CK5/6 (+)
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studies used routinely panels of immunohistochemical
markers to classify breast cancers into subtypes similar
to those previously defined using gene expression ana-
lyses [6]. The recent study was realized by Prat et al. [4].
They defined several immunohistochemical subtypes:
(luminal A, Luminal B, HER2- enriched, basal-like) and
a normal breast-like group that show significant differ-
ences in incidence, survival and response to therapy.
Luminal A (ER positive (ER+) and/or PR positive (PR+),
Her2 negative (Her2-)) with ki67<14%, luminal B (ER +
and/or PR+ with ki67>14%, Her2 positive or negative
(Her2+/-), Her2+/ER − subtype (Her2+, ER−, PR−) and
basal-like (ER−, PR−, Her2−, Cytokeratin 5/6 positive
(CK5/6+) and/or Her1+ (EGFR)). Tumors which were
negative at immunohistochemical staining for all mar-
kers (ER, PR, Her2, Her1, and CK5/6) were considered
unclassified subtype [4]. According to this classification,
we performed immunohistochemical staining for ER,
PR, Her2, Her1, CK8/18, basal CK5/6 and KI67 in paraf-
fin sections from blocks of breast cancer. The aim of the
present study was to estimate the prevalence of breast
cancer subtypes in patients of the north east region of
Morocco, and to correlate between clinical and patho-
logical characteristics.
Methods
Patients this study was approved by Ethical Committee
of Hassan II teaching hospital Center. A total of three
hundred and ninety patients diagnosed with invasive
breast carcinoma were examineted. Clinical information
was retrieved from the medical records. Breast cancers
were classified according to the World Health
Organization (WHO, 2003) [7] while histological grading
and staging were performed according to Modified
Bloom-Richardson classification [8] and American Joint
Committee on Cancer (AJCC) [9], respectively.
Immunohistochemical study
Tumors sections were deparaffinized and rehydrated.
Peroxide blocking was done with 0.4% H2O2. Antigen
retrieval was achieved by heat retrieval using a pressure
cooker. After washing, the slides were treated with pro-
tein blocking agent (UltraTech HRP, Immunotech) then
incubated with the following primary antibodies: anti-
human ER (ER1D5, Immunotech), PR (PR10A9, Immu-
notech), CK5/6 (D5/16B4, Cell Marque), CK8/18 (RTU-
5D3, Novocastra), Ki67 (SP6 Cell Marque). After rinsing
with PBS, the slides were incubated with a secondary
biotinylated antibody (Immunotech). The slides were
then rinsed with PBS. Sections were then incubated
with streptavidin-peroxidase reagent. Staining for the
slides was developed with Amino-Ethyl-Carbazole (Ultra
Tech AEC, Immunotech) and then the slides werecounterstained with hematoxylin, hydrated, and mounted.
For Her2, immunohistochemical was carried out using
with HercepTest (A0485, Dako) according to the com-
mercial instructions for use.
Immunohistochemical surrogate biomarkers of mo-
lecular classification Immunohistochemical subtypes
were defined as follows: Luminal A (ER + and/or PR+,
Her2-, KI67<14%), luminal B (ER + and/or PR+, Her2
+/-, Ki67>14%), basal-like (ER-, PR-, Her2-, and CK5/6+,
CK14+), Her2+/ER-, and unclassified subtype (negative
for all markers) (Table 1). CK8/18 expression was used
for confirmation the luminal subtypes.
Positive controls were included in each staining run
and consisted of breast cancers known to express each
of the antigens of interest. Cases were considered posi-
tive for ER and PR according to standardized guidelines
using a cut-off of ≥1% stained tumour nuclei. Fluores-
cence in situ hybridization (FISH) study
All Her2 score 2+ cases were analyzed by FISH. They
were performed using the PathVysion HER2 DNA Probe
(Abbott Vysis Inc., Downers Grove, IL) according to the
manufacturer’s protocol. The probe cocktail included
the LSI HER-2/neu probe and the CEP17 probe. Fluor-
escence signals were analyzed and digitalized using the
CytoVisionTM image analysis system (Applied Imaging
International Ltd., Newcastle-Upon-Tyne, UK). Between
60 and 100 nuclei were scored for each case. Signal
ratios (HER2: CEP17) ≥ 2, 2 were classified as amplified.
In the absence of positive FISH data, tumors scored 2+
by IHC were considered as negative for HER-2. Her2
was scored based on a 0 to 3 scale according to the cri-
teria set by ASCO (American Society of Clinical Oncol-
ogy/College of American Pathologists) [10]. Scores 0
and 1+ were considered as negative; score 2+ was con-
sidered borderline; and score 3+ was considered as
strongly positive. FISH was performed on the borderline
cases (score 2+).KI67
In breast cancer, immunohistochemical assessment of
the proportion of cells staining for the nuclear antigen
Ki67 has become the most widely used method for com-
paring proliferation between tumor samples. Potential
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ness or resistance to chemotherapy or endocrine ther-
apy, estimation of residual risk in patients on standard
therapy and as a dynamic biomarker of treatment
efficacy in samples taken before, during, and after
neoadjuvant therapy, particularly neoadjuvant endocrine
therapy. Cases were considered positive for ki67 accord-
ing to standardized guidelines using a cut-off of ≥14%
stained tumour nuclei with moderate intensity (Figure 1).
Statistical analysis
Statistical analysis was performed in the Department of
Epidemiology, of the Faculty of Medicine and Pharmacy
of Fez and was carried out using Epi-Info (3.3.2).
Results and discussion
The study was achieved on 390 patients diagnosed
with infiltrating breast cancer and managed at the
Department of pathology in Hassan II University Hos-
pital in Fez. The patient’s average age at diagnosis
was 46 years (ranging from 22 to 92 years). The
tumor clinical stage on first diagnosis, according to
American Joint Committee on Cancer Staging Sys-
tems, showed that 47 women (14.5%) are at stage I,
108 (33%) are at stage II, 114 (35%) are at stage III
and 57 (17.5%) at stage IV. After histological analysis,
the tumor average size was 3.7 ± 2.6 cm (ranging
from 0.2 to 16 cm). Most of these tumors (87, 2%)









Figure 1 Distribution by the proliferation index assessed by Ki 67.5, 4% were invasive lobular carcinomas (ILC), 2%
were metaplastic carcinoma (MC), and few patients
had cancers of rare histology (5, 4%), which were
summarized as “other types” in our study. The histo-
logical grade distribution for luminal B were grade II
(59.9%), grade III (30.6%) but few patients only were
grade I (9,6%) with p<0,0001. Vascular emboli were
detected in 71.2% of patient’s luminal B. The status of
lymph nodes was determined for 326 patients among
which 68, 8% had positive lymph nodes and 12.5%
had distant metastasis.
The immunohistochemical study showed that 67, 1%
patients were ER positives, 63, 7% were PR positive, and
24, 7% were Her2 positive. Therefore, Luminal B subtype
was more prevalent (41.8%), followed by luminal A
(30.5%), basal-like (13, 6%), Her2-overexpressing (9, 2%),
and unclassified subtype (4.9%). The luminal B subtypes
present a higher median tumor size (T2 and T3) as like
basal-like and Her2-overexpressing. IHC subtypes were
significantly different by histological grade (p< 0.00001).
The luminal B also represented a higher percentage of
cases with histological grade II and III (90, 5%) like,
basal-like and Her2-overexpressing subtypes (90, 2% and
96% respectively) and a very low percentage of tumors
with histological grade I (9,6%, 9,8% and 4%, respec-
tively). The Luminal B subtype had 71, 2% vascular em-
boli, approach Her2-overexpressing subtypes (75,6%). In
this study, the luminal B tumors had average percentage
of lymph node metastasis (68, 8%) and distant metastasis< 14%
> 14%
El Fatemi et al. Diagnostic Pathology 2012, 7:170 Page 4 of 7
http://www.diagnosticpathology.org/content/7/1/170(12, 5%). Table 2 Twenty-two patients (12.2%) died be-
cause of cancer-related events during the follow-up.
Among these patients, 25% belong to basal-like, 22% be-
long to unclassified subtype group. 20% to Her2-
overexpressing group, 17% to luminal B and only 5% in
luminal A.
Molecular studies of breast cancer revealed biological
heterogeneity of the disease and opened new perspec-
tives for personalized therapy. While multiple gene
expression-based systems have been developed, current
clinical practice is largely based upon conventionalTable 2 Prevalence of intrinsic subtypes and clinico-patholog
subtype luminal A luminal B
Histological type %
IDC Nos 30,5 41,1
ILC 47,6 42,9






























P=0,0030clinical and pathologic criteria. Digital image analysis
(DA) with multivariate statistics of the data opens new
opportunities in this field [11].
Recently, gene expression studies, using microarray
technology, confirmed that the heterogeneity of clinical
response could be correlated with different molecular
profiles of breast cancers [1]. Arvydas and al reported a
series of tissue microarrays of 109 patients with breast
ductal carcinoma, were stained for a set of 10 IHC mar-
kers (ER, PR, HER2, Ki67, AR, BCL2, HIF-1α, SATB1,
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mated DA is an efficient exploratory tool clarifying com-
plex interdependencies in the breast ductal carcinoma
IHC profiles. Major factor of the aggressive disease
behaviour (i-Grade) is characterized by opposite loadings
of ER/PR/AR/BCL2 and Ki67/HIF-1α. The i-Grade fac-
tor scores represent integral quantitative characteristics
that reveal bimodal distribution and are strongly asso-
ciated with the histological grade and relevant intrinsic
subtypes. In HR-positive tumours, the aggressiveness of
the tumour is best reflected by the combination of Ki67
and ER, rather than Ki67 and BCL2. Inverse relation
between HER2 and PR expression in the HR-positive
tumours which, along with the inverse relation between
Ki67 and ER, may shed the light into the differential
information conveyed by the ER and PR expression.
Remarkably, SATB1 along with HIF-1α reflected the sec-
ond major factor of variation in patients with breast can-
cer; furthermore, in the HR-positive group they were
inversely associated with the HR and BCL2 expression
and represented the major factor contributing to the
variation in the IHC data set. However, this factor was
not associated with the clinicopathologic categories
studied. Biological meaning of this variation remains un-
clear: HIF-1α and SATB1 may convey important bio-
logical messages other than the aggressiveness of the
disease reflected by Ki67 expression and histological
grade. Meanwhile, the authors, support the notion that
the suggested prognostic significance of SATB1 may be
related to its inverse relation to the ER expression. Fi-
nally, this analysis confirms high expression levels of p16
in Triple-negative tumours [12]. In our study, based on
recent updated IHC subtype definition by Prat et al. [4],
we estimated the prevalence of breast cancer subtypes in
patients from the north east Moroccan region and estab-
lished the correlations between clinico-pathological
characteristics. The patients recruited in our university
hospital were younger than in western series; the average
age at diagnosis was 46.8 years. In terms of clinical sta-
ging, only 14.5% patients were diagnosed at stage I,
while 33% were at stage II, 35% at stage III and 17.5% at
stage IV. On the other hand, after histological analysis
the average tumor size was 3.7 cm and 75% of cases
measured more than 2 cm. A majority of tumors were
stage II or III. Our data showed that more than 50% of
patients of all subtypes presented positive lymph nodes
and more than 12% of cases had distant metastasis on
first diagnosis. This could be due to late consultation
during the progression of the disease in our region as
well as to lack of the Medicare coverage, lack of screen-
ing mammography program and women’s awareness
trainings particularly in rural area. The predominant
histology type in this study was invasive cancer (87.4%),
similar to most breast cancer studies worldwide.Overexpression of the protein and/or amplification of
the HER2 gene have been reported in approximately 20
to 30% of breast cancers, similar to what was found in
our patients (24,7%). Her2+ tumors are associated with
either poor prognosis or with response to trastuzumab
[13]. Our results showed a distribution of breast cancer
subtypes non similar to what was reported by other
immunohistochemical studies [4]. In this study, the
prevalence of luminal B (41, 8%) and is the more fre-
quent subtype. Considering the fact that all patients
came from a university hospital the possible effects of a
selection bias should be regarded. Cancer registry avail-
able includes only data from the university hospital and
not all North African population of Morocco. Triple-
negative subtype represented approximately 13, 6% of
our series and 78% of them were basal-like tumors.
These results were similar to what was found in other
studies [4,14]. The basal-like group was defined by
immunohistochemistry, as being negative for ER, PR,
and Her2 and positive for Ck5/6, CK14 and/or Her1
(EGFR). It is important to study whether EGFR is over-
expressed in patients with breast cancer since these
patients can be given specific EGFR molecule tyrosine
kinase inhibitors such as gefitinib and lapatinib [15,16].
There are only a few reports regarding the overexpres-
sion of EGFR, with these studies indicating 8-36% of
breast cancers over express this protein. However, sys-
tematic studies appraising EGFR gene amplification and
mutations in the same set of cases among Chinese fe-
male patients with breast cancer are absent [17-19].
EGFR gene mutations are infrequent in breast cancers.
This suggested that EGFR mutation analysis is not useful
as a screening test for sensitivity to anti-EGFR therapy
for breast cancers [20]. In literature, the luminal B
tumors are associated with poor recurrence-free and
disease-specific survivals in all adjuvant systemic treat-
ment categories including hormone therapy; the identifi-
cation of specific signaling pathways driving luminal B
biology is paramount to improve treatment. Sircoulomb
et al. and Holland et al. have independently identified
the ZNF703 gene, located in chromosomal region 8p12,
as preferentially amplified in luminal B tumours [21].
The natural history of breast cancer involves progres-
sion through defined pathological and clinical stages,
starting with ductal hyperproliferation, with subsequent
evolution into in situ and invasive carcinomas, and
finally into metastatic disease. The majority of invasive
breast cancer develop over long periods of time from
certain pre-existing benign lesions. The best character-
ized premalignant lesions recognized today are referred
to as atypical ductal hyperplasia (ADH), atypical lobular
hyperplasia (ALH), ductal carcinoma in situ (DCIS) and
lobular carcinoma in situ (LCIS). Douglas and al, [22]
reported that Lobular neoplasia (LN) and invasive
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in the same specimen and location of the tumor--in up
to 90% of cases of ILC [23]. Invasive carcinomas were
present with LN in 45.6% of cases, with similar rates of
association with invasive carcinoma and ILC (47.2%).
Bratthauer and Tavassoli stratified the LNs as "lobular
intraepithelial neoplasias" (LIN) and evaluated the fre-
quency of association between LIN subtypes (1, 2, and 3)
and invasive carcinoma. The percentage of LIN 1
(equivalent to ALH) that was associated with invasive
carcinoma was 14%, and 89% of these tumors were
IDCs. In the patients with LIN 3 (equivalent to LCIS),
the frequency of association with IDC and ILC was 23%
and 86%, respectively. The authors concluded that the
advance from LIN 1 to LIN 3 was linked to a 64% in-
crease in the frequency of invasive carcinoma and a
greater than 70% rise in the likelihood of ILC [24].
Apoptosis is a frequent phenomenon in breast cancer
and it can be detected by light microscopy in conven-
tional histopathological sections or by special staining
techniques. Balance between expression status of anti-
apoptotic and pro-apoptotic proteins determines cells to
be alive or not. The key event of apoptosis occurrence is
cascade activation of caspases, and inhibitor of apoptosis
proteins (IAPs) play a important role in caspase inhib-
ition. XIAP is the most potent caspase inhibitor and
Smac is one of the antagonists of XIAP. Down regula-
tion of XIAP expression or applying exogenous Smac
mimics can sensitize tumor cells, especially for breast
cancer cells, to chemotherapeutics and promote apop-
tosis [25,26]. In immunohistochemistry, XIAP and Smac
were positive in cytoplasm of tumor cells with strong or
moderate intensity, respectively. The positive ratio of
XIAP (84.3%, 86/102) was more higher than that of
Smac (33.3%, 34/102), and immunoscore of XIAP was
higher than Smac in IDC too (P < 0.0001). It was note-
worthy that 44 IDC samples were nuclear positive for
XIAP, but none was for Smac. And cytoplasm positive
status of XIAP nuclear positive group was stronger than
the negative group (P = 0.030, 0.047). Otherwise, Smac
immunoscore was prevalent in HER2 positive group
than negative group (P < 0.0001). Remaining data
revealed that the expression status of XIAP/Smac was
not correlated with patient age, tumor size, lymph node
status, histologic grading, expression of ER and PR.
XIAP was a potent protein for apoptosis inhibition and
Smac was an important negative regulator of the former.
Disturbed balance of expression between XIAP and
Smac probably contributed to carcinogenesis and XIAP
positive nuclear labeling was a sign of unfavourable
prognosis in breast invasive ductal carcinoma [27].
Others studies have demonstrated that claudin-6 func-
tions as a cancer suppressor in human MCF-7 breast
cancer cells. The growth inhibitory effect could beattributed to inhibition of cell proliferation and induc-
tion of apoptosis. Claudins (CLDNs) constitute a family
of integral membrane proteins and have been identified
as prominent structural components of tight junction
( TJ ) strands [28,29]. TJs are junctional complexes
which mediate cell-to-cell adhesion in epithelial and en-
dothelial cellular sheets [30], and which affect cell po-
larity and tight junction formation [28]. Guo and al
reported that the apoptosis signal-regulating kinase 1
(ASK1) expression is low in breast cancer, and the levels
of ASK1 mRNA and protein expression are correlated
with that of claudin-6. They have identified a novel
mechanism responsible for the pro-apoptosis function of
claudin-6, and ASK1 may become a target for breast
cancer treatments. The integrins, a family of transmem-
brane glycoproteins, play a major role in invasive and
metastatic processes. Integrins are involved in cell adhe-
sion in both cell-extracellular matrix and cell-cell inter-
actions, and particularly, beta 1 integrin is involved in
proliferation and differentiation of cells in the develop-
ment of epithelial tissues. The putative role of beta 1 in-
tegrin expression on survival and metastasis in patients
with breast invasive ductal carcinoma (IDC) was studied
by Santos and al [31]. His study showed that beta1 integ-
rin can be a marker of poor prognosis in breast cancer.
Beta 1 integrin was overexpressed in 32.8% of IDC and
was related with HER-2 and VEGF expression, and it
had a significant relationship with metastasis and death ,
survival analysis showed that the overexpression of this
protein is very significant in specific survival (number of
months between diagnosis and death caused by the dis-
ease). Immunohistochemistrey is important to determin-
ate the tumors of unknown origin (5-15%) and specially
breast cancer metastasis (1.5%). Mammaglobin (MAG)
antibody in the immunohistochemical panel for the
detection of tumors of unknown origin contributed to
the detection of metastasis of breast cancer. The diag-
nostic strategy with the highest positive predictive value
(88%) included hormone receptors and mammaglobin in
serial manner [32].
Conclusions
We have shown that simple IHC-based classification of
breast tumors can be helpful. Since the predictive power
of IHC criteria appears to be similar to that of gene
expression analysis, this information can be used to
improve therapeutic decisions, mainly for luminal B,
Her2- overexpressing and basal-like subtypes. The
luminal B subtype was associated with a poor prognosis
and unfavorable clinico-pathological characteristics. In
addition, findings concerning tumors stages are alarming
and highlight the importance of early screening and the
urgent need to improve women’s awareness of breast
cancer in our region. Our results should be confirmed
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and hospitals including patients coming from different
regions of Morocco.
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